ClinicalTrials.Veeva

Menu

Optina Eye to Heart Connection

O

Optina Diagnostics

Status

Completed

Conditions

Coronary Artery Disease

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT05199428
DOC100469

Details and patient eligibility

About

This is a prospective cross-sectional, single-center retinal imaging study expecting to enroll approximately 400 male and female subjects ≥ 18 years of age. Subjects having undergone clinically-indicated coronary angiography or coronary computed tomography angiography (CCTA) within one month of consent at the Montreal Heart Institute (MHI) will be screened for inclusion in the study.

Full description

This is a prospective cross-sectional, single-center retinal imaging study expecting to enroll aproximately 400 (280 CAD and 120 control) male and female subjects ≥ 18 years of age. Subjects having undergone clinically-indicated invasive coronary angiography or coronary computed tomography angiography (CCTA) within one month of signed consent will be screened for inclusion in the study.

Subjects will be recruited at the Montreal Heart Institute (MHI). During the screening visit, the investigator will review inclusion/exclusion criteria and the following information will be collected: demographic data including age and sex, relevant medical history including risk factors (hypertension, diabetes, dyslipidemia, smoking and obesity), history of CAD, concomitant cardiovascular medications and laboratory tests (lipid profile, fasting glucose) Subjects who provide written informed consent will undergo cognitive evaluation and an ophthalmic examination to identify any ocular exclusion criteria. All eligible subjects will then undergo hyperspectral retinal imaging using a Metabolic Hyperspectral Retinal Camera (MHRC)

Safety will be assessed through reporting of serious adverse events (SAEs) related to retinal imaging procedures.

Enrollment

308 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Ability and willingness to give written informed consent
  • Age 18 years or older at the time of informed consent
  • Stable (non-emergent) typical or atypical symptoms suspicious for CAD (e.g., chest pain, chest tightness, chest burning, shoulder pain, palpitations, jaw pain, or non-chest pain symptoms such as dyspnea or worsening effort tolerance.
  • Patients having undergone clinically-indicated invasive coronary angiography or coronary computed tomography angiography within one month before consent signature

Exclusion criteria

  1. At Screening Visit 1:

    1. Asymptomatic subjects
    2. Previous coronary revascularization (e.g., coronary artery bypass graft surgery, stenting)
    3. Subjects being evaluated for other cardiac diseases (e.g., valvular disease, cardiomyopathy)
    4. Pregnant or breastfeeding women
  2. At Study Visit 2 or Ocular Exclusion Criteria:

    1. Medium or high opacity of the lens
    2. Bleeding in vitreous
    3. Pupillary dilation inadequate or contraindicated
    4. Deficient visual fixation
    5. Refractive error outside of the range -15 to +15
    6. Inability to obtain satisfactory images with the MHRC

Trial contacts and locations

1

Loading...

Central trial contact

Shannon Campbell; Julie Antonelle Orellina

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems